Information Library

Lower portfolio & investment risks

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • QUINTILES AND ALLERGAN ANNOUNCE CO-PROMOTION AGREEMENT

    September 25, 2009 – Quintiles Transnational Corp. and Allergan, Inc. today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR®.

  • Rebalancing Risk to Transform R&D

    June 3, 2009
    A strategic approach to re-balancing the main components of biopharma company risk: portfolio, operational and resource.

  • James C. Kirk

    March 25, 2009
    Jim joined Eidetics in 1988 from senior management positions in consumer and industrial product marketing, strategy, and development positions at Ocean Spray Cranberries and Gillette Company. Previously at Ocean Spray, Jim successfully spearheaded the company’s new Ingredient Division.

  • Adrian McKemey, Ph.D.

    March 25, 2009
    Adrian leads the Product Development and Commercialization consulting practice at Quintiles Global Consulting.

  • Jim Featherstone, Ph.D.

    March 25, 2009
    Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice.

  • Jay Norman

    March 24, 2009
    President – Quintiles Consulting Jay brings 25 years of experience in the consulting industry and a strong track record of growth, most recently with Diamond Management and Technology Consultants, where he served as President and Chief Operating Officer.

  • Leveraging a $2 Billion Portfolio

    August 1, 2008
    A Pharma TV interview with Ben Cons

  • Reducing Risk

    August 1, 2008
    A Pharma TV interview with Ben Cons

  • Pressures and Opportunities

    August 1, 2008
    A Pharma TV interview with Ben Cons

  • A New Gold Standard

    May 1, 2008
    May 2008 - John Doyle, DrPH, practice leader for market access at Quintiles Consulting, discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.

Page 1 of 1 (10 results)

Tell Us What You Think

Rate your Quintiles.com experience

Subscribe to Email Based on Your Interests

Set preferences